Posters 2021
DOI: 10.1136/gutjnl-2021-bsg.187
|View full text |Cite
|
Sign up to set email alerts
|

PMO-48 Both single and multiple switching between infliximab biosimilars can be safe and effective in ibd

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Multiple switchings also appear to be effective and safe according to several studies [ 14 , 15 ]. In a multicenter prospective cohort study, Hanzel J et al observed similar rates of clinical and biochemical remission at 12 months in patients undergoing multiple switches, a single switch between biosimilars, or a single switch from the originator to CT-P13 [ 16 ].…”
Section: Discussionmentioning
confidence: 99%
“…Multiple switchings also appear to be effective and safe according to several studies [ 14 , 15 ]. In a multicenter prospective cohort study, Hanzel J et al observed similar rates of clinical and biochemical remission at 12 months in patients undergoing multiple switches, a single switch between biosimilars, or a single switch from the originator to CT-P13 [ 16 ].…”
Section: Discussionmentioning
confidence: 99%